BioCryst to Present at J.P. Morgan Healthcare Conference
BioCryst
Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Jon
Stonehouse, President and Chief Executive Officer of BioCryst is
scheduled to present and provide a corporate summary and update
regarding the Company at the 31st annual J.P. Morgan
Healthcare Conference in San Francisco on Thursday, January 10, 2012 at
10:30 a.m. Pacific Time.
Links to a live audio webcast and replay of the presentation may be
accessed on the BioCryst website events page at http://investor.shareholder.com/biocryst/events.cfm.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals designs, optimizes and develops novel small
molecule drugs that block key enzymes involved in infectious and
inflammatory diseases, with the goal of addressing unmet medical needs
of patients and physicians. BioCryst currently has two late-stage
development programs: peramivir, a viral neuraminidase inhibitor for the
treatment of influenza, and ulodesine, a purine nucleoside phosphorylase
(PNP) inhibitor for the treatment of gout. In addition, BioCryst has
several early-stage programs: BCX4161 and a next generation oral
inhibitor of plasma kallikrein for hereditary angioedema, BCX4430, a
broad spectrum antiviral for hemorrhagic fevers, and BCX5191, a
nucleoside analog inhibitor of HCV RNA polymerase (NS5B) for hepatitis
C. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including
statements regarding future results and achievements. These statements
involve known and unknown risks, uncertainties and other factors which
may cause our actual results, performance or achievements to be
materially different from any future results, performances or
achievements expressed or implied by the forward-looking statements.
Please refer to the documents BioCryst files periodically with the SEC
and located at http://investor.shareholder.com/biocryst/sec.cfm.
BCRXW
